NASDAQ$CGEM
Cullinan Oncology Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Announced second quarter 2023 financial results and provided a corporate update.
Cullinan Oncology reported a cash and investment position of $512.1 million as of June 30, 2023, which is expected to provide runway into 2026. The company also announced the initiation of a Phase 3 study of zipalertinib and presented initial clinical monotherapy data for CLN-619 at ASCO 2023.
- Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer (NSCLC) patients (REZILIENT-3) is open for enrollment.
- Initial monotherapy clinical data for CLN-619 was presented at ASCO 2023 Annual Meeting; monotherapy expansion cohorts in endometrial and cervical cancers were initiated.
- The first patient was dosed in Phase 1 study of CLN-978 in relapsed/refractory (R/R) B Cell non-Hodgkin lymphoma (B-NHL).
- Cash and investment position of $512.1 million as of June 30, 2023, which is expected to provide runway into 2026.
Headline financials
Revenue & EPS history
Cullinan Oncology · Revenue · Quarterly
$100K
Forward guidance
Cullinan Oncology expects its cash resources to provide runway into 2026 based on its current operating plan.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+0.5%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-2.1%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+13.5%
Q1 2022
Best reaction
-10.8%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -2.6% | +7.7% | -10.0% | |
| Q3 2025 | +0.8% | +6.7% | +44.9% | |
| Q2 2025 | -10.8% | -7.7% | -11.3% | |
| Q1 2025 | +2.3% | +1.3% | +5.8% | |
| Q4 2024 | +1.9% | -3.8% | -5.1% | |
| Q3 2024 | -2.8% | -2.8% | -20.8% | |
| Q1 2024 | -9.7% | -9.1% | -28.4% | |
| Q4 2023 | -6.2% | -8.7% | -1.8% | |
| Q3 2023 | -2.7% | -11.1% | -17.7% | |
| Q2 2023 | +4.3% | -1.4% | -0.6% | |
| Q1 2023 | +1.2% | -5.3% | +36.0% | |
| Q4 2022 | -1.5% | +3.3% | -9.1% | |
| Q3 2022 | +3.8% | +1.0% | -3.0% | |
| Q2 2022 | -5.6% | +0.8% | -3.5% | |
| Q1 2022 | +13.5% | +6.8% | +12.1% | |
| Q4 2021 | +8.8% | +3.0% | -8.6% | |
| Q3 2021 | -4.5% | -10.1% | -28.8% | |
| Q2 2021 | +7.8% | +3.8% | +8.0% | |
| Q1 2021 | +2.2% | +12.4% | +13.1% | |
| Q4 2020 | +9.5% | +8.4% | -13.9% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro